1.
PD-1/PD-L1抑制剂在NSCLC一线、二线及辅助治疗中的临床研究
Clinical researches of PD-1/PD-L1 inhibitors in first-line, second-line and adjuvant therapy with NSCLC
| Regimen | Trials | Types of NSCLC | PD-L1 selection | Line of therapy | ORR | mPFS (mon) | mOS (mon) |
| NSCLC: non-small cell lung cancer; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; mPFS: mean progression-free survival; mOS: mean overall survival; NR: not reach. | |||||||
| Nivolumab | CheckMate-017 | Squamous | None | 2nd | 20.00% | 3.5 (HR=0.62) | 9.2 (HR=0.59) |
| Nivolumab | CheckMate-057 | Non-squamous | None | ≥2nd | 19.00% | 2.3 (HR=0.92) | 12.2 (HR=0.73) |
| Nivolumab | CheckMate-078 | All | None | 2nd | 16.90% | 2.8 (HR=0.77) | 11.9 (HR=0.64) |
| Nivolumab | CheckMate-026 | All | ≥5% | 1st | 26.00% | 4.2 (HR=1.15) | 14.4 (HR=1.02) |
| Nivolumab+ Ipilimumab | CheckMate-227 | All | None | 1st | 45.30% | 7.2 (HR=0.58) | / |
| Pembrolizumab | Keynete-010 | All | ≥1% (2 mg/kg) | ≥2nd | 18.00% | 3.9 (HR=0.88) | 10.4 (HR=0.71) |
| ≥1% (10 mg/kg) | 18.00% | 4.0 (HR=0.79) | 12.7 (HR=0.61) | ||||
| ≥50% (2 mg/kg) | 29.00% | 5.0 (HR=0.59) | 14.9 (HR=0.54) | ||||
| ≥50% (10 mg/kg) | 30.00% | 5.2 (HR=0.59) | 17.3 (HR=0.50) | ||||
| Pembrolizumab | Keynote-024 | All | ≥50% | 1st | 44.80% | 10.3 (HR=0.50) | 30.0 (HR=0.63) |
| Pembrolizumab | Keynote-042 | All | ≥1% | 1st | 27.30% | 5.4 (HR=1.07) | 16.7 (HR=0.81) |
| ≥20% | 33.40% | 6.2 (HR=0.94) | 17.7 (HR=0.77) | ||||
| ≥50% | 39.50% | 7.1 (HR=0.81) | 20.0 (HR=0.69) | ||||
| Pembrolizumab | Keynote-021 | Non-squamous | All population | 1st | 56.70% | 24.0 (HR=0.53) | NR (HR=0.56) |
| < 1% | 57.00% | / | / | ||||
| ≥1% | 54.00% | ||||||
| 1%-49% | 26.00% | ||||||
| ≥50% | 80.00% | ||||||
| Pembrolizumab | Keynote-189 | Non-squamous | All population | 1st | 47.60% | 8.8 (HR=0.52) | NR (HR=0.49) |
| < 1% | 32.30% | / | HR=0.59 | ||||
| 1%-49% | 48.40% | HR=0.55 | |||||
| ≥50% | 61.40% | HR=0.42 | |||||
| Pembrolizumab | Keynote-407 | Squamous | All population | 1st | 57.90% | 6.4 (HR=0.56) | 15.9 (HR=0.64) |
| < 1% | 63.20% | 6.3 (HR=0.68) | HR=0.61 | ||||
| ≥1% | / | / | HR=0.65 | ||||
| 1%-49% | 49.50% | 7.2 (HR=0.56) | HR=0.57 | ||||
| ≥50% | 60.30% | 8.0 (HR=0.37) | HR=0.64 | ||||
| Atezolizumab | POPLAR | All | None | 2nd | 17.00% | 2.7 (HR=0.94) | 12.6 (HR=0.73) |
| Atezolizumab | OAK | All | None | ≥2nd | 14.00% | 2.7 (HR=0.96) | 13.8 (HR=0.73) |
| Atezolizumab | IMpower130 | Non-squamous | All population | 1st | 49.20% | 7.0 (HR=0.64) | 18.6 (HR=0.79) |
| < 1% | / | 6.2 (HR=0.72) | 15.2 (HR=0.81) | ||||
| 1%-49% | 8.3 (HR=0.61) | 23.7 (HR=0.70) | |||||
| ≥50% | 6.4 (HR=0.51) | 17.3 (HR=0.84) | |||||
| Atezolizumab | IMpower131 | Squamous | All population | 1st | 49.00% | 6.3 (HR=0.71) | 14.0 (HR=0.96) |
| < 1% | 44.00% | 5.7 (HR=0.81) | / | ||||
| 1%-49% | 52.00% | 6.0 (HR=0.70) | |||||
| ≥50% | 60.00% | 10.1 (HR=0.44) | |||||
| Atezolizumab | IMpower132 | Non-squamous | All population | 1st | 47.00% | 7.6 (HR=0.60) | 18.1 (HR=0.81) |
| < 1% | 44.00% | 8.5 (HR=0.45) | / | ||||
| 1%-49% | 38.00% | 6.2 (HR=0.80) | |||||
| ≥50% | 72.00% | 10.8 (HR=0.46) | |||||
| Atezolizumab | IMpower150 | Non-squamous | All population | 1st | 56.00% | 8.3 (HR=0.62) | 19.2 (HR=0.78) |
| < 1% | / | 7.1 (HR=0.77) | 25.2 (HR=0.70) | ||||
| 1%-49% | 8.3 (HR=0.56) | 20.3 (HR=0.80) | |||||
| ≥50% | 12.6 (HR=0.39) | 17.1 (HR=0.82) | |||||
| Avelumab | JAVELIN Lung 200 | All | ≥1% | 2nd | 19.00% | 3.4 (HR=1.01) | 11.4 (HR=0.90) |
| Durvalumab | PACIFIC | All | None | Adjuvant therapy | 28.40% | 16.8 (HR=0.52) | NR (HR=0.68) |